Stock Evaluator: Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences, Inc. NERV

$2.00 -0.12 -5.66%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 137,661
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics NERV Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $99.7 $203.5 23%
Shares Out (Mil) 75.3 55.2 56%
Institutional Ownership 99.1% 93.3% 84%
Float (Mil) 36.4 40.4 39%
Beta 0.01 1.05 6%
Avg Daily Volume (000s) 158 569 41%
Price Change
(52-week)
(53.5%) 38.8% 20%
Growth NERV Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (174.7%) (10.7%) 0%
EPS (5yr) (147.7%) 15.4% 0
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 56.4% (15.7%) 95%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na 1 1
Current EPS ($0.180) ($0.540) ($0.420)
Month Ago EPS na ($0.570) ($0.420)
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS na ($0.570) ($0.420)
Year/Year Chg (2.7%) (98.4%) (99.6%)
Financials NERV Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($291) ($44) 4%
EPS (TTM) ($7.705) ($1.400) 6%
Operating Cash Flow (TTM) (Mil) ($31) ($35) 12%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $60 $4 40%
Enterprise Value (Q1) (Mil) $126 $142 24%
Valuation NERV Industry
Median
Percentile
(All Stocks)
P/B na 1.96 na
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios NERV Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (460.3%) (47.0%) 0%
ROE 440.3% (51.8%) 99%
Liabilities to Assets 187.3% 29.6% 99%
F-Score 2 3 7%

Minerva Neurosciences, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors